The company is actively engaging with investors through major healthcare conferences and demonstrating confidence in its business. The underlying context shows strong commercial performance with record Q2 2026 revenues of $74.3 million (88% YoY growth) and 1.7 million total VOQUEZNA prescriptions filled, indicating successful market adoption of its lead product.
Strong Q1 2026 financial performance with 104% year-over-year revenue growth to $58.3 million and 1.35 million total prescriptions filled demonstrates successful commercialization of VOQUEZNA. Active engagement at major medical conferences and expanding clinical data presentation indicate growing market presence and physician adoption.
Articles that tag PHAT but are mainly about other companies.
Vonoprazan (VOQUEZNA) entered Phase II clinical trial for EoE in November 2025 with topline data expected in 2027, providing exposure to the high-growth EoE market segment.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
